In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Treponema pallidum is the causative organism for Syphilis and cannot be cultivated in vitro, resulting in a need for specific IVD tests, rather than the more usual bacteriology testing. GlobalData uses proprietary data and analytics to provide a comprehensive report on the treponema pallidum tests market in the US. Buy the latest report here.

In 2022, GlobalData’s Market Model methodology determined that the leading player in the treponema pallidum tests market in the US was Abbott Laboratories followed by Arlington Scientific, Becton Dickinson and Co, Bio-Rad Laboratories, Cardinal Health, DiaSorin, F. Hoffmann-La Roche, H.U. Group, Siemens and Trinity Biotech.

Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.

The identification of the Treponema pallidum pathogen is usually performed by using Direct and Indirect detection methods. It includes Venereal Disease Research Laboratory (VDRL) Tests, Rapid Plasma Reagin (RPR) Tests, Unheated Serum Reagin (USR) Tests, Treponema Passive Particle Agglutination (TPPA) Tests, Treponema Pallidum Hemagglutination (TPHA) Tests, Fluorescent Treponemal Antibody Absorption (FTA-ABS) Tests, Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests and Other Tests. Direct Detection Methods: Direct detection methods include the detection of Treponema pallidum by microscopic examination of fluids and smears from lesions, histological examination of tissues, or nucleic acid amplification methods such as polymerase chain reaction (PCR). Nucleic acid amplification methods are not standardized for the testing of Treponema pallidum as they are under investigation. Indirect Detection Methods: Indirect detection methods for Treponema pallidum include serological tests which are broadly classified into Non-treponemal and Treponemal tests. Non-Treponemal Tests: Non-Treponemal tests are used to detect the antibodies or biomarkers that occur as a result of the cellular damage caused due to the syphilis spirochete. Centers for Disease Control and Prevention (CDC) approved Non-treponemal standard tests which include the VDRL (Venereal Disease Research Laboratory) slide tests, the RPR (Rapid Plasma Reagin) card tests, the USR (Unheated Serum Reagin) tests and the TRUST (Toluidine Red Unheated Serum Test).

The treponema pallidum tests market in the US can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.

For the latest analysis of the market size treponema pallidum tests in the US, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.